📣Case Study: Helping Avacta Overcome Complex Cytotoxic Chemistry, from Discovery to Clinic in 14 Months

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimization Campaign - CCS1477

    CellCentric Lead Optimization Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Webinar and Podcast

Get it right from the start – How to build confidence through the hit discovery process.

Integrating FIDA™ and Biacore™ SPR for optimal results.

Get it right from the start – How to build confidence through the hit discovery process.

Integrating FIDA™ and Biacore™ SPR for optimal results

Biophysical discovery depends on confidence in your reagents from the very beginning. When protein quality, stability, and behavior are fully understood early in a campaign, downstream hit identification and characterization become faster, more reliable, and far less prone to costly surprises.

As drug discovery programs increasingly target challenging proteins, novel modalities, and complex biological systems, researchers need workflows that can generate robust data while reducing risk at every stage. But how can you confidently assess reagent quality, troubleshoot difficult assays, and ensure that promising hits are genuinely worth pursuing?

In this webinar, experts from Sygnature Discovery, Fida Biosystems, and Cytiva explore how combining FIDA™ (Flow Induced Dispersion Analysis) and Biacore™ SPR creates a powerful hit discovery workflow that helps researchers build confidence from the start. Together, these complementary technologies provide insights into reagent quality, molecular interactions, and hit validation, enabling teams to make better decisions earlier in discovery programs.

Drawing on real-world case studies, the discussion will showcase how integrated biophysical approaches can help overcome common challenges, unlock previously difficult targets, and generate the high-quality data needed to advance the most promising molecules.

Watch the webinar now.

In This Webinar You’ll Learn

Start with Better Reagents

Why understanding protein quality, stability, and behaviour early can improve confidence throughout the discovery process.

De-Risk Challenging Targets

How integrated biophysical workflows can support difficult targets, including complex and membrane-associated proteins.

Understand Complex Sensorgrams

Approaches for investigating unexpected binding behaviour and gaining greater confidence in your data.

Generate More Reliable Hits

How combining solution-based and surface-based technologies can strengthen hit validation and prioritization.

Improve Decision-Making Earlier

Why reducing uncertainty at the start of a campaign can save valuable time and resources downstream.

Key Discussion Topics

  • The growing challenge of working with difficult targets and emerging therapeutic modalities
  • The role of reagent assessment and quality control in successful hit discovery campaigns
  • How FIDA™ and Biacore™ SPR provide complementary information within a single workflow
  • Strategies for improving assay robustness and reducing false positives or misleading results
  • Lessons learned from real-world discovery programmes and biophysical screening campaigns
  • How integrated technology platforms can accelerate progression from screening to qualified hits

Ready to Explore the Full Discussion? Watch it below.

Resources

Related Research & Resources

View all Articles